Status:
COMPLETED
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
Lead Sponsor:
AstraZeneca
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18-130 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination w...
Eligibility Criteria
Inclusion
- Clinical Diagnosis of colon or rectal cancer
- No prior systemic therapy for metastatic disease. Any adjuvant/neoadjuvant oxaliplatin therapy must have been received \>12 months prior to study entry and adjuvant/neoadjuvant 5-FU must have been received \>6 months prior to study entry.
Exclusion
- Prior treatment with a VEGF Inhibitor, including bevacizumab and cediranib.
- Poorly controlled hypertension
Key Trial Info
Start Date :
August 30 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 19 2015
Estimated Enrollment :
1814 Patients enrolled
Trial Details
Trial ID
NCT00384176
Start Date
August 30 2006
End Date
August 19 2015
Last Update
April 14 2017
Active Locations (280)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Anniston, Alabama, United States
2
Research Site
Birmingham, Alabama, United States
3
Research Site
Casa Grande, Arizona, United States
4
Research Site
Tucson, Arizona, United States